Integral Health Asset Management LLC Decreases Stock Position in Inspire Medical Systems, Inc. (NYSE:INSP)

Integral Health Asset Management LLC trimmed its stake in shares of Inspire Medical Systems, Inc. (NYSE:INSP - Free Report) by 37.5% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 100,000 shares of the company's stock after selling 60,000 shares during the quarter. Inspire Medical Systems accounts for 1.6% of Integral Health Asset Management LLC's holdings, making the stock its 22nd largest holding. Integral Health Asset Management LLC owned about 0.33% of Inspire Medical Systems worth $18,538,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently bought and sold shares of INSP. First Horizon Advisors Inc. increased its holdings in shares of Inspire Medical Systems by 885.7% in the 4th quarter. First Horizon Advisors Inc. now owns 138 shares of the company's stock valued at $26,000 after acquiring an additional 124 shares during the last quarter. Huntington National Bank raised its holdings in Inspire Medical Systems by 228.3% during the fourth quarter. Huntington National Bank now owns 174 shares of the company's stock worth $32,000 after purchasing an additional 121 shares in the last quarter. Harbour Investments Inc. raised its holdings in Inspire Medical Systems by 101.0% during the fourth quarter. Harbour Investments Inc. now owns 197 shares of the company's stock worth $37,000 after purchasing an additional 99 shares in the last quarter. AlphaQuest LLC lifted its position in shares of Inspire Medical Systems by 7,275.0% during the 4th quarter. AlphaQuest LLC now owns 295 shares of the company's stock worth $55,000 after buying an additional 291 shares during the last quarter. Finally, Quadrant Capital Group LLC boosted its holdings in shares of Inspire Medical Systems by 61.9% in the 4th quarter. Quadrant Capital Group LLC now owns 327 shares of the company's stock valued at $61,000 after buying an additional 125 shares in the last quarter. Hedge funds and other institutional investors own 94.91% of the company's stock.

Insider Buying and Selling

In other Inspire Medical Systems news, Director Shawn Mccormick sold 360 shares of the company's stock in a transaction dated Friday, May 2nd. The shares were sold at an average price of $160.00, for a total value of $57,600.00. Following the transaction, the director now directly owns 24,046 shares in the company, valued at approximately $3,847,360. This represents a 1.48% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 2.30% of the stock is currently owned by insiders.

Inspire Medical Systems Trading Down 4.0%

Shares of Inspire Medical Systems stock traded down $6.31 on Thursday, reaching $149.51. 620,721 shares of the stock were exchanged, compared to its average volume of 563,438. The firm has a market capitalization of $4.41 billion, a PE ratio of 86.42, a PEG ratio of 2.86 and a beta of 1.39. Inspire Medical Systems, Inc. has a 1-year low of $123.00 and a 1-year high of $225.00. The business has a fifty day moving average price of $156.45 and a two-hundred day moving average price of $177.54.

Inspire Medical Systems (NYSE:INSP - Get Free Report) last posted its quarterly earnings results on Monday, May 5th. The company reported $0.10 earnings per share for the quarter, beating analysts' consensus estimates of ($0.23) by $0.33. Inspire Medical Systems had a return on equity of 8.19% and a net margin of 6.67%. The firm had revenue of $201.32 million for the quarter, compared to the consensus estimate of $194.89 million. During the same period in the previous year, the business earned ($0.34) earnings per share. The company's revenue for the quarter was up 22.7% compared to the same quarter last year. Research analysts expect that Inspire Medical Systems, Inc. will post 2.16 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the stock. Royal Bank of Canada reduced their price target on shares of Inspire Medical Systems from $260.00 to $215.00 and set an "outperform" rating for the company in a research report on Tuesday, April 15th. Truist Financial decreased their target price on Inspire Medical Systems from $250.00 to $235.00 and set a "buy" rating for the company in a research report on Tuesday, February 11th. Morgan Stanley cut their price target on Inspire Medical Systems from $220.00 to $200.00 and set an "overweight" rating on the stock in a research report on Tuesday, May 6th. Robert W. Baird raised their target price on shares of Inspire Medical Systems from $230.00 to $236.00 and gave the stock an "outperform" rating in a research report on Tuesday, May 6th. Finally, JPMorgan Chase & Co. cut their target price on shares of Inspire Medical Systems from $235.00 to $195.00 and set an "overweight" rating on the stock in a report on Tuesday, May 6th. Three investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat.com, Inspire Medical Systems presently has a consensus rating of "Moderate Buy" and a consensus target price of $211.91.

About Inspire Medical Systems

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.